Back to Screener

Oculis Holding AG Warrants (OCSAW)

Price$6.50
Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)53.22%
Price vs S&P 500 (4W)-36.06%
VGM Score65.82

All Metrics

Price vs S&P 500 (YTD)33.71%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.00M
52-Week High$22.64
26-Week Price Return69.15%
13-Week Price Return43.46%
3-Month Return Std Dev141.00%
Year-to-Date Return43.46%
5-Day Price Return-25.17%
Month-to-Date Return-23.77%
Price vs S&P 500 (13W)33.71%
Beta1.22x
52-Week Low$4.85
mGradeB
vgmGradeB
Show chart for

Industry Peers — Pharmaceuticals(550)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
OCSAWOculis Holding AG Warrants
B$6.50
LLYEli Lilly & Co.DBB$1082.20
JNJJohnson & JohnsonCCC$223.51
ABBVABBVIE INC.DCC$212.93
MRKMerck & Co., Inc.CCC$115.17
NVSNovartis AGCCC$145.68
AZNAstraZeneca PLCDBC$179.71
NVONovo-Nordisk A/SBBC$44.07
ABTAbbott LaboratoriesCCD$87.78
PFEPfizer Inc.BCC$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary SharesCCC$34.64

About

Oculis Holding AG is a biopharmaceutical company developing targeted therapies for eye diseases and vision disorders. Its pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and other neuro-ophthalmologic conditions including glaucoma and diabetic retinopathy. The company employs topical and disease-modifying approaches to address significant unmet needs in ophthalmology.